Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

Technology appraisal guidance
Reference number: TA355
Published: 23 September 2015
Last updated: 02 July 2021

Download (PDF)

What has NICE said?

Edoxaban (Lixiana) is recommended as an option for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation who have one or more risk factors, such as:

heart failure, high blood pressure or diabetes
had a stroke or transient ischaemic attack before
aged 75 years or older.

What does this mean for me?

If you have non‑valvular atrial fibrillation and your doctor thinks that edoxaban is the right treatment, you should be able to have the treatment on the NHS.

Edoxaban should be available on the NHS within 3 months of the guidance being issued.